Table 1 Demographic data and clinical characteristics among septic patients with and without SLE
From: Impact of systemic lupus erythematosus on the 5-year survival of critically ill septic patients
| SLE | Non-SLE | p value | |
|---|---|---|---|
| (n = 513) | (n = 2052) | ||
| Age, years | 48.8 ± 16.3 | 48.8 ± 16.3 | 1 |
| Gender | 1 | ||
| Female | 442 (86.2) | 1768 (86.2) | |
| Male | 71 (13.8) | 284 (13.8) | |
| Urbanisation levels | < 0.001 | ||
| Urban | 164 (32.0) | 475 (23.1) | |
| Suburban | 221 (43.1) | 947 (46.2) | |
| Rural | 128 (25.0) | 630 (30.7) | |
| Low insured incomea | 243 (47.4) | 1141 (55.6) | < 0.001 |
| CCI without renal disease, mean ± SD | 2.9 ± 1.7 | 2.4 ± 2.6 | < 0.001 |
| CCI without renal disease, group | < 0.001 | ||
| 0 | 4 (0.8) | 608 (29.6) | |
| 1–3 | 359 (70.0) | 930 (45.3) | |
| > 3 | 150 (29.2) | 514 (25.0) | |
| Recent hospitalised infectionb | 78 (15.2) | 199 (9.7) | < 0.001 |
| Medications | |||
| Glucocorticoid use | 506 (98.6) | 1606 (78.3) | < 0.001 |
| Glucocorticoid dosage, mg/dayc | 47.9 ± 85.1 | 15.7 ± 40.2 | < 0.001 |
| Glucocorticoid dosage groupc | < 0.001 | ||
| 0 mg/day | 7 (1.4) | 447 (21.8) | |
| 0-5 mg/day | 27 (5.3) | 678 (33.0) | |
| ≥ 5 mg/day | 479 (93.4) | 927 (45.2) | |
| DMARD | |||
| Methotrexate | 20 (3.9) | 45 (2.2) | 0.032 |
| Sulfasalazine | 10 (1.9) | 14 (0.7) | 0.014 |
| Hydroxychloroquine | 331 (64.5) | 36 (1.8) | < 0.001 |
| Immunosuppressantsd | 294 (57.3) | 98 (4.8) | < 0.001 |